Clinical Trial Update: A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pharmacokinetics, safety, tolerability, immunogenicity, and pharmacodynamics of GSK2800528 in healthy subjects; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• GSK2800528

Snippet

Sponsor: GlaxoSmithKline | Conditions: Psoriasis | Phase 1 | Status: COMPLETED